New peanut allergy treatment will benefit thousands of children
The new treatment, known as Palforzia, could help children between the ages of 4 and 17 by helping them develop their tolerance to peanuts.
The National Institute for Health and Excellence in Care has recommended the new treatment which contains “precise and gradually increasing amounts of peanut protein”, which will help the body build tolerance and effectively reduce the severity of reactions. allergic in case of exposure to peanuts.
Peanuts are the cause of one of the most common food allergies in children, with between 0.5% and 2% of children in the UK having some form of allergic reaction.
I’m glad we’re in a position to recommend a treatment that may improve the quality of life for children and youth with peanut allergy and their caregivers.
Gillian Leng, Managing Director NICE
Professor Gillian Leng, Managing Director of NICE, said: âA peanut allergy can have serious consequences on the lives of children, youth, their families and their caregivers. Although it is rare for a peanut allergy to be fatal in the UK, the consequences of accidental exposure to peanuts can be serious, with some people needing to self-administer adrenaline and receive treatment. emergency if exposed to peanuts â.
Depending on the severity, peanut allergies in children can cause a wide range of symptoms such as hives and rashes, itching around the mouth and throat, shortness of breath and, in acute cases, severe pain. anaphylaxis.
During clinical trials, which involved the use of the new treatment as well as placebos, showed that those who received Palforzia increased the number of children who could tolerate a minimum of 1000 milligrams of peanut protein, which equates to about three peanuts.